Virtual Navigator for Real-Time PET-CT/Ultrasound Fusion Imaging

Esaote, Genoa (ITALY), October 6th 2014 - In 2002 Esaote designed and introduced its own revolutionary cutting-edge system dedicated to Fusion Imaging modality, the Virtual Navigator, specially focused on Interventional Radiology.

The need of developing such an advanced system arose because of the intrinsic characteristics of the Ultrasound imaging modality. Ultrasound is the most widely diffused imaging modality for real-time guidance/monitoring of diagnostic and therapeutic interventional procedures in all their phases, also due to its nearly universal availability, portability, ease of use and cost-effective features. However, Ultrasound has also some limitations, like patient’s body habitus, bowel gas distention, insufficient sensitivity for the detection of small lesions in some conditions.

In recent years real-time Ultrasound (US) image fusion with a pre-acquired second imaging dataset - Computed Tomography (CT) and/or Magnetic Resonance Imaging (MRI) - has become widely used both for diagnostic purposes and image-guided interventional procedures, especially in clinical applications where liver is the main anatomical region to be examined.

Esaote Virtual Navigator represents the leading-edge system that combines the real-time visualization of enhanced Ultrasound images with all the other advanced complementary imaging technologies. The fusion of US with CT/MRI imaging allows the Ultrasound real-time focusing on the panoramic view offered by CT/MR scanning.

As a further step ahead Esaote introduces the capability of adding the fundamental information coming from Positron Emission Tomography (PET) imaging to US modality, using CT scans coming from PET-CT examinations only for PET-Ultrasound fusion registration.

The possibility to perform US-guided interventional procedures by exploiting real-time functional information from the tissues examined with PET, eventually supported by Contrast-Enhanced Ultrasound (CEUS), represents an outstanding valuable additional tool. This innovative modality can improve the anatomical localization of actively uptaking lesions, especially when the target lesion is poorly visualized by the Ultrasound modality itself.
Esaote Virtual Navigator can even enable easier differentiation between uptaking and non-uptaking lesions on PET. The Esaote CnTI™ advanced technology used to perform CEUS procedures at the maximum level, and its direct fusion with pre-treatment PET data, can ensure the outmost confidence also in the follow-up phase.

A new era in Interventional Ultrasound Imaging has started with the Esaote Virtual Navigator, a Step Ahead in Fusion Imaging.

Download the ESAOTE at IOSF 2013 - Interventional Oncology Sans Frontières video [YouTube, 4 parts]

For further details, please contact: luca.lodigiani@esaote.com

Courtesy of:
Enzo Di Mauro, MD - Department of Nuclear Medicine, General Hospital of Busto Arsizio (VA), ITALY
Marco Solbiati - Faculty of Biomedical Engineering, Polytechnic, Milan, ITALY
Luigi Solbiati, MD - Department of Interventional Oncology Radiology, General Hospital of Busto Arsizio (VA), ITALY

© Copyright Esaote October 2014
ABOUT ESAOTE

With €276.1 million in consolidated sales in 2013 (of which 65% were generated from international markets), Esaote Group is a leading player in the biomedical equipment sector, with a particular focus on ultrasound, dedicated magnetic resonance, and software for managing the diagnostic process. Esaote has over 1,335 employees, 19% of which are employed in R&D activities. Esaote has industrial and research units in Italy (Genoa, Florence, Naples), the Netherlands (Maastricht) and China (Shenzhen). Esaote is internationally recognised as one of the “Top Ten” diagnostic imaging companies in the world and enjoys the co-operation of worldwide scientific and clinical research centres and universities. Esaote has filed more than 120 international patents.

Information about the Esaote Group and its products is available at www.esaote.com

The use of contrast agents in the USA is limited by FDA to left ventricle opacification and visualization of the left ventricular endocardial border. Technology and features are system/configuration dependent. Specifications subject to change without notice. Information might refer to products or modalities not yet approved in all countries. For further details, please contact your Esaote sales representative.

To learn more, please refer to:


© Copyright Esaote October 2014